Browsing by Author "Kiraz, S"

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    The Relationship between Self and Time in Grounding of Metaphysics: An Analysis with Reference to Kant and Heidegger
    Kiraz, S
    Heidegger interpreted Kant's Critique of Pure Reason, in an effort to ground metaphysics. This study aims to analyze the relationship between self and time as the key point of that interpretation with reference to Kant and Heidegger. Unlike Kant, Heidegger focuses on and awards significance to the concept of time in order to attain ontological knowledge. By doing so, the philosopher pushes the boundary that Kant draws between knowable and unknowable. In order to reveal how Heidegger achieves that, one should first shed light on how self and time relate to the concepts of transcendency, infiniteness, finiteness, thinking and self-consciousness. This article, which also aims to interpret the said relationality, consequently, holds that Heidegger, reduces the distance between humans and reality through his attempt to ground metaphysics.
  • No Thumbnail Available
    Item
    Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study
    Ortiz-Fernández, L; Saruhan-Direskeneli, G; Alibaz-Oner, F; Kaymaz-Tahra, S; Coit, P; Kong, XF; Kiprianos, AP; Maughan, RT; Aydin, SZ; Aksu, K; Keser, G; Kamali, S; Inanc, M; Springer, J; Akar, S; Onen, F; Akkoc, N; Khalidi, NA; Koening, C; Karadag, O; Kiraz, S; Forbess, L; Langford, CA; McAlear, CA; Ozbalkan, Z; Yavuz, S; Çetin, GY; Alpay-Kanitez, N; Chung, S; Ates, A; Karaaslan, Y; McKinnon-Maksimowicz, K; Monach, PA; Ozer, HTE; Seyahi, E; Fresko, I; Cefle, A; Seo, P; Warrington, KJ; Ozturk, MA; Ytterberg, SR; Cobankara, V; Onat, AM; Duzgun, N; Bicakcigil, M; Yentür, SP; Lally, L; Manfredi, AA; Baldissera, E; Erken, E; Yazici, A; Kisacik, B; Kasifoglu, T; Dalkilic, E; Cuthbertson, D; Pagnoux, C; Sreih, A; Reales, G; Wallace, C; Wren, JD; Cunninghame-Graham, DS; Vyse, TJ; Sun, Y; Chen, HY; Grayson, PC; Tombetti, E; Jiang, LD; Mason, JC; Merkel, PA; Direskeneli, H; Sawalha, AH
    Takayasu arteritis is a rare inflammatory disease of large arteries. We performed a genetic study in Takayasu arteritis comprising 6,670 individuals (1,226 affected individuals) from five different populations. We discovered HLA risk factors and four non-HLA susceptibility loci in VPS8, SVEP1, CFL2, and chr13q21 and reinforced IL12B, PTK2B, and chr21q22 as robust susceptibility loci shared across ancestries. Functional analysis proposed plausible underlying disease mechanisms and pinpointed ETS2 as a potential causal gene for chr21q22 association. We also identified >60 candidate loci with suggestive association (p < 5 x 10(-s)) and devised a genetic risk score for Takayasu arteritis. Takayasu arteritis was compared to hundreds of other traits, revealing the closest genetic relatedness to inflammatory bowel disease. Epigenetic patterns within risk loci suggest roles for monocytes and B cells in Takayasu arteritis. This work enhances understanding of the genetic basis and pathophysiology of Takayasu arteritis and provides clues for potential new therapeutic targets.
  • No Thumbnail Available
    Item
    PERFORMANCE OF 2022 ACR/EULAR GPA, EGPA AND MPA CLASSIFICATION CRITERIA IN TURKISH VASCULITIS STUDY GROUP PROSPECTIVE COHORT (TRVAS)
    Bolek, EC; Ayan, G; Bilgin, E; Ediboglu, ED; Duran, E; Kardas, C; Yildirim, TD; Ozdemir, B; Ogüt, TS; Karabacak, M; Cagdas, OS; Yildirim, R; Erpek, E; Ozgur, D; Akleylek, C; Acar, EA; Uludogan, BC; Unaldi, E; Uzun, GS; Ekici, ZOM; Firlatan, B; Kart-Bayram, S; Kutu, ME; Mutlu, MY; Armagan, B; Gercik, O; Bitik, B; Kücük, H; Yilmaz, N; Bilge, NSY; Celik, S; Kilic, L; Kasifoglu, T; Yazici, A; Bes, C; Erden, A; Erbasan, F; Asicioglu, E; Alibaz-Oner, F; Omma, A; Cefle, A; Yazisiz, V; Ozturk, MA; Direskeneli, H; Kiraz, S; Onen, F; Akar, S; Karadag, O
  • No Thumbnail Available
    Item
    THE COST OF CARE OF RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS PATIENTS IN TERTIARY CARE RHEUMATOLOGY UNITS IN TURKEY
    Malhan, S; Pay, S; Ataman, S; Dalkilic, E; Dinc, A; Erken, E; Ertenli, I; Ertugrul, E; Gogus, F; Hamuryudan, V; Inanc, M; Karaaslan, Y; Karadag, O; Karakoc, Y; Keskin, G; Kisacik, B; Kiraz, S; Oksel, F; Oksuz, E; Parildar, T; Sari, I; Soy, M; Senturk, T; Taylan, A
  • No Thumbnail Available
    Item
    The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey
    Malhan, S; Pay, S; Ataman, S; Dalkilic, E; Dinc, A; Erken, E; Ertenli, I; Ertugrul, E; Gogus, F; Hamuryudan, V; Inanc, M; Karaaslan, Y; Karadag, O; Karakoc, Y; Keskin, G; Kisacik, B; Kiraz, S; Oksel, F; Oksuz, E; Pirildar, T; Sari, I; Soy, M; Senturk, T; Taylan, A
    Objectives To determine the direct and indirect costs due to rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients in Turkey. Methods An expert panel was convened to estimate the direct and indirect costs of care of patients with RA and AS in Turkey. The panel was composed of 22 experts chosen from all national tertiary care rheumatology units (n=53). To calculate direct costs, the medical management of RA and AS patients was estimated using cost-of-illness methodology. To measure indirect costs, the number of days of sick leave, the extent of disability, and the levels of early retirement and early death were also evaluated. Lost productivity costs were calculated using the human capital approach, based on the minimum wage. Results The total annual direct costs were 2,917.03 Euros per RA patient and 3,565.9 Euros for each AS patient. The direct costs were thus substantial, but the indirect costs were much higher because of extensive morbidity and mortality rates. The total annual indirect costs were 7,058.99 Euros per RA patient and 6,989.81 for each AS patient. Thus, the total cost for each RA patient was 9,976.01 Euros and that for an AS patient 10,555.72 Euros, in Turkey. Conclusion From the societal perspective, both RA and AS have become burden in Turkey. The cost of lost productivity is higher than the medical cost. Another important conclusion is that indirect costs constitute 70% and 66% of total costs in patients with RA and AS, respectively.
  • No Thumbnail Available
    Item
    Impact of rheumatoid arthritis in Turkey: a questionnaire study
    Direskeneli, H; Akkoç, N; Bes, C; Çakir, N; Çefle, A; Çobankara, V; Dalkiliç, E; Dinç, A; Ertenli, T; Gül, A; Hamuryudan, V; Inanç, M; Kalyoncu, U; Karaaslan, Y; Kasifoglu, T; Keser, G; Keskin, G; Kisacik, B; Kiraz, S; Masatlioglu, S; Onat, AM; Özbek, S; Öztürk, MA; Pamuk, ÖN; Pay, S; Pirildar, T; Sayarlioglu, M; Senel, S; Sentürk, T; Tasan, D; Terzioglu, E; Yazici, A; Yücel, E
    Objective Unmet needs of rheumatoid arthritis (RA) patients regarding physician/patient communication, treatment preferences and quality of life issues were investigated in a Turkish survey study. Methods The study was conducted with the contribution of 33 rheumatologists, and included 519 RA patients. The study population included patients who had been on biologic therapy for >6 months and were still receiving biologic therapy (BT group), and those who were biologic naive, but found eligible for biologic treatment (NBT group). Of the RA patients, 35.5% initially had a visit to an internal disease specialist, 25.5% to a physical therapy and rehabilitation specialist, and 12.2% to a rheumatology specialist for their RA complaints. The diagnosis of RA was made by a rheumatologist in 48.2% of patients. Results The majority of RA patients (86.3%) visit their doctor within 15-week intervals. Most of the physician-patient communication focused on disease symptoms (99.0%) and impact of the disease on quality of life (61.8%). The proportion of RA patients who perceived their health status as good/very good/excellent was higher in the BT group than in the NBT group (74.3% vs. 51.5%, p<0.001). However, of those RA patients in the NBT group, only 24.8% have been recommended to start a biologic treatment by their doctors. With respect to dose frequency options, once-monthly injections were preferred (80%) to a bi-weekly injection schedule (8%). Conclusion In conclusion, RA patients receiving biologic therapy reported higher rates of improved symptoms and better quality of life and seemed to be more satisfied with their treatment in our study.